Latest Financials News

Amplia Therapeutics reports strong progress in its pancreatic cancer drug development, completing the ACCENT trial recruitment ahead of schedule and initiating a new US trial, while managing a $6.57 million loss for FY25.

Mount Hope Mining Limited has announced a non-renounceable pro-rata Loyalty Option Offer to raise approximately $103,125, aiming to bolster exploration funding and reward shareholder loyalty.

RTG Mining has completed a A$15.3 million tranche 2 placement, bolstering its financial position to advance the Mabilo gold and copper project and explore new opportunities.

Galileo Mining has agreed to extend key terms of its lithium joint venture with Mineral Resources at the Norseman project, adjusting payment timelines and earn-in periods to support ongoing exploration.

Austco Healthcare has completed its strategic acquisition of New Zealand’s G&S Technologies, enhancing its healthcare communication offerings and direct sales reach in the region.

Merchant House International Limited reported a 38% reduction in net loss for FY2025, driven by asset sales and operational wind-down. The company is moving towards divesting remaining assets, delisting from ASX, and winding up.

Manuka Resources has announced a comprehensive 10-year mine plan to produce 13.2 million ounces of silver plus gold credits from its Wonawinta and Mt Boppy projects, leveraging existing infrastructure and an upgraded processing plant.

Horizon Minerals has acknowledged an unintentional breach of ASX Listing Rule 15.7 after sharing details of a $30 million placement with the media before the official market announcement.

Emmerson Resources’ joint venture partner Tennant Mining has begun commercial gold production at the Nobles Project near Tennant Creek, setting the stage for potential royalty payments and future development opportunities.

Wingara AG Limited reported an 18% revenue increase to $3.5 million for FY25 but posted a reduced net loss of $1.47 million, reflecting a strategic pause in fodder operations amid challenging market conditions.

Cardiex Digital Vascular Biomarkers announces a A$6.5 million equity raise to fund inventory, marketing, product development, and debt repayment, aiming to solidify its position in the expanding cardiovascular health market.

Cardiex Limited has raised $2.4 million through an institutional placement and launched a fully underwritten entitlement offer to raise up to $4.1 million, aiming to scale its CONNEQT Pulse device.